Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown. The current study was to evaluate the secukinumab-assocaited adverse events (AEs) through data minin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, Ding, Yufeng, Liu, Yanxin, Wu, Pan, He, Xucheng, Zhang, Qilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214234/
https://www.ncbi.nlm.nih.gov/pubmed/35754494
http://dx.doi.org/10.3389/fphar.2022.862508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214234/
https://www.ncbi.nlm.nih.gov/pubmed/35754494
http://dx.doi.org/10.3389/fphar.2022.862508

Ejemplares similares